Novo Nordisk A/S (NVO)

52.27
0.43 0.82
NYSE : Health Technology
Prev Close 52.70
Open 52.42
Day Low/High 52.14 / 52.81
52 Wk Low/High 41.23 / 52.84
Volume 1.19M
Avg Volume 1.48M
Exchange NYSE
Shares Outstanding 1.86B
Market Cap 126.54B
EPS 2.50
Div & Yield 0.87 (1.71%)

Latest News

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

Jim Cramer: A Tale of Two Stocks

Jim Cramer: A Tale of Two Stocks

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

Dealing With Biotech Stocks That Face Setbacks

Dealing With Biotech Stocks That Face Setbacks

Knowing when to continue to fish or cut bait is something that develops over time in this space.

Renewable Electricity To Completely Power Novo Nordisk US Operations In Early 2020

Renewable Electricity To Completely Power Novo Nordisk US Operations In Early 2020

New $70 million investment in 105-megawatt solar panel installation in North Carolina underscores 'Circular for Zero' commitment to environment

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs

Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs

Gilead Sciences is partnering with Novo Nordisk to help combat liver disease.

Downgrades Are Important: Cramer's 'Mad Money' Recap (Monday 4/8/19)

Downgrades Are Important: Cramer's 'Mad Money' Recap (Monday 4/8/19)

Jim Cramer says these downgrades may be well-reasoned, but he wants to know if they're correct.

Ollie's Bargain Outlet, Novo Nordisk, Avnet: 'Mad Money' Lightning Round

Ollie's Bargain Outlet, Novo Nordisk, Avnet: 'Mad Money' Lightning Round

Jim Cramer weighs in on Ollie's Bargain Outlet, Novo Nordisk, Avnet, Cabot Corp., Helmerich & Payne, Amarin, Golar LNG, Nio and more.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Stocks Mixed as Asia Gets China Trade Boost, Wall Street Rides Earnings Wave

Stocks Mixed as Asia Gets China Trade Boost, Wall Street Rides Earnings Wave

Global stocks were mixed Wednesday, with stronger-than-expected trade data from China, as well as the expectation of further stimulus from Beijing, boosting shares in Asia while softer earnings in Europe held down gains for stocks on the Continent.

Exiting Eli Lilly Position

We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Pharma firm's new diabetes drug showed positive test results.

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results

The Danish company's shares are enjoying their best day since May 2.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Buying More Lilly

We are picking up LLY shares into weakness, below our basis in the process.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'

Novo Boosts Exploration Team

Novo Boosts Exploration Team

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.

TheStreet Quant Rating: B+ (Buy)